CVS Health Corporation
HealthcareNYSE:CVS · New York Stock Exchange
+$1.30 today
Vol 6.13M · Avg 7.98M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$407.9B of revenue converted into $2.9B of net income for the selected period. Gross margin is 13.9% and net margin is 0.7%, showing how much revenue survives after costs and taxes. EPS is $2.27, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $402.1B +7.8% | $372.8B +4.2% | $357.8B +10.9% | $322.5B +10.4% | $292.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $346.7B +7.9% | $321.4B +6.0% | $303.3B +13.2% | $268.0B +11.7% | $240.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $55.4B +7.7% | $51.4B -5.6% | $54.4B -0.1% | $54.5B +4.6% | $52.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 13.8% -0.0pp | 13.8% -1.4pp | 15.2% -1.7pp | 16.9% -0.9pp | 17.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $0 -100.0% | $41.2B | $0 | $0 | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $45.0B +4.9% | $42.9B +5.4% | $40.7B -12.6% | $46.5B +19.9% | $38.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.6B +0.2% | $4.6B +5.3% | $4.4B +3.4% | $4.2B -5.8% | $4.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | $9.9B -27.9% | $13.7B -24.8% | $18.2B +47.4% | $12.3B -29.6% | $17.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 2.5% -1.2pp | 3.7% -1.4pp | 5.1% +1.3pp | 3.8% -2.2pp | 6.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $10.4B +21.9% | $8.5B -38.0% | $13.7B +72.8% | $8.0B -40.2% | $13.3B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 2.6% +0.3pp | 2.3% -1.6pp | 3.8% +1.4pp | 2.5% -2.1pp | 4.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.1B +5.4% | $3.0B +11.3% | $2.7B +16.2% | $2.3B -8.6% | $2.5B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$8.2B -248.4% | -$2.4B +7.9% | -$2.6B -21.3% | -$2.1B +23.6% | -$2.8B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $2.1B -65.3% | $6.1B -45.0% | $11.2B +91.4% | $5.8B -44.6% | $10.5B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 0.5% -1.1pp | 1.6% -1.5pp | 3.1% +1.3pp | 1.8% -1.8pp | 3.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $408.0M -73.9% | $1.6B -44.3% | $2.8B +85.9% | $1.5B -40.8% | $2.5B | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.8B -61.7% | $4.6B -44.7% | $8.3B +93.6% | $4.3B -46.1% | $8.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 0.4% -0.8pp | 1.2% -1.1pp | 2.3% +1.0pp | 1.3% -1.4pp | 2.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 -61.7% | $4 -43.6% | $6 +97.3% | $3 -45.2% | $6 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -62.0% | $4 -43.4% | $6 +98.5% | $3 -45.2% | $6 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.3B +0.6% | $1.3B -2.0% | $1.3B -2.1% | $1.3B -0.5% | $1.3B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.3B +0.7% | $1.3B -2.2% | $1.3B -2.5% | $1.3B -0.5% | $1.3B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Bristol-Myers Squibb Company
NYSE:BMY
$116.66B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.57B
GSK plc
NYSE:GSK
$106.59B
Medtronic plc
NYSE:MDT
$103.09B
McKesson Corporation
NYSE:MCK
$94.82B
Elevance Health Inc.
NYSE:ELV
$87.26B
HCA Healthcare, Inc.
NYSE:HCA
$85.72B
Cigna Corporation
NYSE:CI
$78.84B
Cencora, Inc.
NYSE:COR
$54.67B
Humana Inc.
NYSE:HUM
$45.32B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CVS generate?
CVS Health Corporation (CVS) reported $402.07B of revenue in fiscal 2025.
Is CVS profitable?
CVS Health Corporation (CVS) reported $1.77B of net income, with a net margin of 0.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.